NYSE:BDX - Becton Dickinson and Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$236.91 -0.52 (-0.22 %)
(As of 04/26/2019 10:20 AM ET)
Previous Close$237.43
Today's Range$236.0550 - $239.00
52-Week Range$208.62 - $265.87
Volume98,727 shs
Average Volume1.21 million shs
Market Capitalization$63.74 billion
P/E Ratio21.52
Dividend Yield1.32%
Beta1.21
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, monoclonal antibodies and kits, reagent systems, bench-side solutions, and molecular indexing and next-generation sequencing sample preparation products, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, thoracic and abdominal drainage, and surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Receive BDX News and Ratings via Email

Sign-up to receive the latest news and ratings for BDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP07588710
Phone201-847-6800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.98 billion
Cash Flow$18.9376 per share
Book Value$78.25 per share

Profitability

Net Income$311 million

Miscellaneous

Employees76,032
Market Cap$63.74 billion
Next Earnings Date5/9/2019 (Confirmed)
OptionableOptionable

Becton Dickinson and (NYSE:BDX) Frequently Asked Questions

What is Becton Dickinson and's stock symbol?

Becton Dickinson and trades on the New York Stock Exchange (NYSE) under the ticker symbol "BDX."

How often does Becton Dickinson and pay dividends? What is the dividend yield for Becton Dickinson and?

Becton Dickinson and announced a quarterly dividend on Wednesday, January 23rd. Stockholders of record on Friday, March 8th will be paid a dividend of $0.77 per share on Friday, March 29th. This represents a $3.08 annualized dividend and a dividend yield of 1.29%. The ex-dividend date of this dividend is Thursday, March 7th. View Becton Dickinson and's Dividend History.

How were Becton Dickinson and's earnings last quarter?

Becton Dickinson and Co (NYSE:BDX) posted its earnings results on Tuesday, February, 5th. The medical instruments supplier reported $2.70 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $2.58 by $0.12. The medical instruments supplier earned $4.16 billion during the quarter, compared to the consensus estimate of $4.10 billion. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. Becton Dickinson and's revenue for the quarter was up 35.1% on a year-over-year basis. During the same quarter last year, the company earned $2.48 earnings per share. View Becton Dickinson and's Earnings History.

When is Becton Dickinson and's next earnings date?

Becton Dickinson and is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Becton Dickinson and.

How can I listen to Becton Dickinson and's earnings call?

Becton Dickinson and will be holding an earnings conference call on Thursday, May 9th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

What guidance has Becton Dickinson and issued on next quarter's earnings?

Becton Dickinson and updated its FY 2019 earnings guidance on Tuesday, February, 5th. The company provided earnings per share (EPS) guidance of $12.05-12.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $12.12. The company issued revenue guidance of $17.342-17.501 billion, compared to the consensus revenue estimate of $17.43 billion.

What price target have analysts set for BDX?

11 Wall Street analysts have issued 1 year target prices for Becton Dickinson and's shares. Their predictions range from $175.00 to $280.00. On average, they anticipate Becton Dickinson and's share price to reach $257.4545 in the next year. This suggests a possible upside of 8.2% from the stock's current price. View Analyst Price Targets for Becton Dickinson and.

What is the consensus analysts' recommendation for Becton Dickinson and?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Becton Dickinson and in the last year. There are currently 4 hold ratings, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Becton Dickinson and.

Has Becton Dickinson and been receiving favorable news coverage?

Press coverage about BDX stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Becton Dickinson and earned a coverage optimism score of 1.1 on InfoTrie's scale. They also assigned press coverage about the medical instruments supplier a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the next several days.

Who are some of Becton Dickinson and's key competitors?

What other stocks do shareholders of Becton Dickinson and own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Becton Dickinson and investors own include Johnson & Johnson (JNJ), Cardinal Health (CAH), NVIDIA (NVDA), Walt Disney (DIS), Home Depot (HD), General Electric (GE), Exxon Mobil (XOM), Alibaba Group (BABA), Visa (V) and Chevron (CVX).

Who are Becton Dickinson and's key executives?

Becton Dickinson and's management team includes the folowing people:
  • Mr. Vincent A. Forlenza, Chairman & CEO (Age 66)
  • Mr. Thomas E. Polen Jr., Pres & COO (Age 46)
  • Mr. Christopher R. Reidy, Exec. VP, CFO & Chief Admin. Officer (Age 62)
  • Mr. Samrat S. Khichi, Exec. VP & Gen. Counsel (Age 52)
  • Mr. Patrick K. Kaltenbach, Exec. VP & Pres of the Life Sciences Segment (Age 56)

Who are Becton Dickinson and's major shareholders?

Becton Dickinson and's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Ronna Sue Cohen (2.13%), Investec Asset Management LTD (0.31%), Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.22%), Waverton Investment Management Ltd (0.18%), BTIM Corp. (0.18%) and Bristol John W & Co. Inc. NY (0.12%). Company insiders that own Becton Dickinson and stock include Alexandre Conroy, Charles R Bodner, David F Melcher, Ellen R Strahlman, Gary M Cohen, James C Lim, James W Borzi, Jeffrey S Sherman, John E Gallagher, Linda M Tharby, Nabil Shabshab, Ribo Alberto Mas, Stephen Sichak, Thomas E Polen Jr, Timothy M Ring and Vincent A Forlenza. View Institutional Ownership Trends for Becton Dickinson and.

Which institutional investors are selling Becton Dickinson and stock?

BDX stock was sold by a variety of institutional investors in the last quarter, including Eastern Bank, Los Angeles Capital Management & Equity Research Inc., Atalanta Sosnoff Capital LLC, Rhenman & Partners Asset Management AB, Palisade Asset Management LLC, Pennsylvania Trust Co, Oppenheimer Asset Management Inc. and Gillespie Robinson & Grimm Inc.. Company insiders that have sold Becton Dickinson and company stock in the last year include Alexandre Conroy, Charles R Bodner, James C Lim, James W Borzi, Nabil Shabshab, Ribo Alberto Mas, Thomas E Polen Jr, Timothy M Ring and Vincent A Forlenza. View Insider Buying and Selling for Becton Dickinson and.

Which institutional investors are buying Becton Dickinson and stock?

BDX stock was purchased by a variety of institutional investors in the last quarter, including Ronna Sue Cohen, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, Alta Capital Management LLC, Bristol John W & Co. Inc. NY, Ellis Investment Partners LLC, Ellis Investment Partners LLC, Pacer Advisors Inc. and Abner Herrman & Brock LLC. View Insider Buying and Selling for Becton Dickinson and.

How do I buy shares of Becton Dickinson and?

Shares of BDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Becton Dickinson and's stock price today?

One share of BDX stock can currently be purchased for approximately $237.9010.

How big of a company is Becton Dickinson and?

Becton Dickinson and has a market capitalization of $64.01 billion and generates $15.98 billion in revenue each year. The medical instruments supplier earns $311 million in net income (profit) each year or $11.01 on an earnings per share basis. Becton Dickinson and employs 76,032 workers across the globe.

What is Becton Dickinson and's official website?

The official website for Becton Dickinson and is http://www.bd.com.

How can I contact Becton Dickinson and?

Becton Dickinson and's mailing address is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. The medical instruments supplier can be reached via phone at 201-847-6800.


MarketBeat Community Rating for Becton Dickinson and (NYSE BDX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  443 (Vote Outperform)
Underperform Votes:  522 (Vote Underperform)
Total Votes:  965
MarketBeat's community ratings are surveys of what our community members think about Becton Dickinson and and other stocks. Vote "Outperform" if you believe BDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/26/2019 by MarketBeat.com Staff

Featured Article: Buyback

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel